* If you want to update the article please login/register
Background: Multiple clinical trials are currently ongoing in the National Cancer Institute Surgery Branch, in which patients are given autologous lymphocytes with anti-tumor enzymes produced from either peripheral blood mononuclear cells or tumor-infiltrating lymphocytes. All adoptive cell therapy protocols recommend that certain cell characteristics be tested and met prior to enrollment. Objectives: To obtain autologous blood, stem cells, and/or tumor tissue from patients with cancer diagnosis and/or ex vivo generation of autologous anti-tumor lymphocytes for future enrollment in a NCI-SB adoption cell therapy clinical trial. Eligibility: Patients with cancer must be >=18 years of age and pass the laboratory safety inspection for infection that was included in all the cell therapy clinical trials. Healthy volunteers for PBMC must meet the FDA's safety evaluation requirements for donation of blood products, including HBsAg, HBc, HCV, HIV, HTLV, Trypanosoma cruzi, West Nile Virus, and syphilis. Volunteers for whole blood donation must meet the safety evaluation criteria established by the NIH Clinical Center Department of Transfusion Medicine Blood Bank for screening of allogeneic whole blood donors. Appesis and/or tumor resection will be performed as a result of future treatment and/or research purposes once a cancer patient has been found to be a candidate for one of the NCI-SB clinical trials.
Source link: https://clinicaltrials.gov/ct2/show/NCT00068003
Allogeneic BMT is a curative therapy for severe SCD treatment with stable, mixed donor chimerism following BMT's eviction of the sickle cell phenotype by virtue of increased donor red cell proliferation in comparison to SCD's ineffective erythropoiesis. We predict that the hematologic parameters associated with red cell survival in patients with SCD vs. healthy donors can be used to determine the correct hemoglobin required to solve SCD's red cell pathology. Objectives: Primary Objective: To determine and compare red blood cell survival in patients with SCD, patients with SCT, and healthy donors, as well as validate the association of red cell survival with established markers of increased red cell survival. Secondary Endpoint: Red blood cell survival remains a prime target for primary endpoints: Red blood cell proliferation is linked to hematologic variables.
Source link: https://clinicaltrials.gov/ct2/show/NCT04476277
The pathophysiology of sickle cell disease is incompletely understood. The normal change of red blood cells into sickle cells leads to post-capillary stream abnormalities. During the thrombotic process, Tanguay's Thrombo-inflammation model was introduced to describe the relationship between hemostasis, platelets, and embedded immune cells during the thrombotic process. During a regular health check-in, blood samples will be collected. Platelet-leukocytes aggregates Physiotic eicosanoids produced by platelets and immune cells; platelet-leukocyte aggregates Plasmatic eicosanoids produced by platelets and immune cells; platelet-leukocyte aggregates Plasmatic eicosanoids produced by platelet and immune cells In vitro platelet reactivity; dynamic thrombus formation in normal and pathologic arterial blood stream Platelet's Inflammasome Platelet strom.
Source link: https://clinicaltrials.gov/ct2/show/NCT05646888
The interrogating antibody coats the microchannel surface and captures the cell population of interest, without processing, incubation, or in vitro manipulation. Cellular adhesion to experimental biological surfaces that are made up of subcellular components can also be measured by the SCD biochip. The SCD biochip is both simple and flexibly flexible, whereby the population of concern is retained on the chip and quantitated in situ.
Source link: https://clinicaltrials.gov/ct2/show/NCT02824471
In most tissues, Glucose transporter 1 is expressed at low amounts as the transporter that controls basal glucose flux levels. Human erythrocytes may play a role in glucose storage, particularly when the serum carrying capacity for glucose becomes limited. However, most G1D patients also have deficiencies in GLUT1 levels and glucose uptake in their erythrocytes, and a potential contributor to disease pathogenesis is likely. Hypothesergic mice lacking GLUT1 are not able to test the hypothesis because they do not fully recapitulate the clinical presentation of G1D patients and do not properly repeat G1D patients' clinical presentation and metabolic adaptationion to G1D. A safe and cost-effective treatment for patients with sickle cell anemia is red blood cell exchange. RBCx has the ability to change G1D patients' treatment in a dramatic way.
Source link: https://clinicaltrials.gov/ct2/show/NCT04137692
This protocol will enable the establishment of a registry of biospecimens from people affected by sickle cell disease to identify and analyze the disease's root cause, as well as other aspects of the disease's pathogenesis and natural history. Subject consent may also be required for the continued storage and analysis of clinical and research results, as well as biospecimens obtained from other NIH Institutional Review Board-approved protocols.
Source link: https://clinicaltrials.gov/ct2/show/NCT00081523
As a control, this is a 2-year controlled, double-blind, placebo-randomized Phase 2 clinical trial comparing the effectiveness of reducing the incidence of respiratory disease in sickle-cell disease of daily oral vitamin D3 with monthly bolus oral vitamin D3 in sickle-cell disease. Eligible participants will be first tested to determine their blood vitamin D levels. At baseline and at 24 months, children over 5 years old who can cooperate and comprehend the procedure will have a lung function test.
Source link: https://clinicaltrials.gov/ct2/show/NCT04170348
Blastic plasmacytoid dendritic cell neoplasm is a rare hematologic disorder. The final diagnosis of BPDCN depends on a specific immunophenotype. BPDCN acute myeloid and monocytic leukemias, precursor lymphoblastic T-cell leukemia/lymphomas, and T- and NK/T cell lymphomas can all be helpful in excluding potential mimics of BPDCN acute myeloid and monocytic leukemia, precursor lymphoblastic T-cell lymphomas and T- and NK/T cell lymphomas. The bulk of patients receive multi-agent chemotherapy with AML or ALL therapy protocols, although a few patients are undergoing allogeneic stem cell transplantation. This is a multicenter, international prospective, and retrospective registry with the intention of gathering data from patients with a diagnosis of BPDCN globally. The Immune Oncology Research Institute will perform quality control and data management, with questionnaires. Patient demographics BPDCN characteristics Patient characteristics BPDCN characteristics BPDCN characteristics Outcomes are death causes of death The following statistics will be collected: patient characteristics BPDCN characteristics Patient characteristics BPDCN characteristics Outcomes Causes of death BPDCN characteristics The following information will be collected by questionnaires: Patient characteristics BPDCN characteristics BPDCN characteristics The following information will be collected by the Immune.
Source link: https://clinicaltrials.gov/ct2/show/NCT05430971
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions